Skip to main content
. Author manuscript; available in PMC: 2020 Apr 1.
Published in final edited form as: Mol Cancer Res. 2018 Nov 28;17(4):839–844. doi: 10.1158/1541-7786.MCR-18-0924

Figure 2.

Figure 2.

A and B, Ixazomib upregulates cell-cycle regulators and inhibits antiapoptotic proteins: Raji and Daudi cells were treated with the indicated concentrations of ixazomib for 24 hours. At the end of treatment, total cell lysates were prepared and immunoblot analyses were performed for cell-cycle–regulatory and antiapoptotic proteins. The expression levels of β-actin in the lysates served as the loading control.